The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Lyra Therapeutics Inc shares valued at $124,062 were sold by PERCEPTIVE ADVISORS LLC on Nov 13 ’25. At $3.90 per share, PERCEPTIVE ADVISORS LLC sold 31,810 shares. The insider’s holdings dropped to 14,026 shares worth approximately $49091.0 following the completion of this transaction.
Also, PERCEPTIVE ADVISORS LLC sold 8,745 shares, netting a total of over 35,499 in proceeds. Following the sale of shares at $4.06 each, the insider now holds 17,239 shares.
Before that, PERCEPTIVE ADVISORS LLC had sold 5,320 shares from its account. In a trade valued at $22,954, the 10% Owner traded Lyra Therapeutics Inc shares for $4.31 each. Upon closing the transaction, the insider’s holdings decreased to 5,320 shares, worth approximately $63427.0.
As published in a research note from Jefferies on May 07, 2024, Lyra Therapeutics Inc [LYRA] has been rated down from a Buy to a Hold and the price target has been revised to $0.50 from $10. Analysts at H.C. Wainwright downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early May. As of May 07, 2024, BofA Securities has decreased its “Buy” rating to a “an Underperform” for LYRA. Earlier on May 06, 2024, William Blair downgraded its rating. Their new recommendation was “a Mkt perform” for LYRA stock which previously was a “an Outperform”.
Analyzing LYRA Stock Performance
On last trading session, Lyra Therapeutics Inc [NASDAQ: LYRA] rose 21.53% to $3.5. The stock’s lowest price that day was $2.95, but it reached a high of $4.16 in the same session. During the last five days, there has been a surge of approximately 0.86%. Over the course of the year, Lyra Therapeutics Inc shares have dropped approximately -62.96%. Shares of the company reached a 52-week high of $37.50 on 06/02/25 and a 52-week low of $2.84 on 11/25/25.
Support And Resistance Levels for Lyra Therapeutics Inc (LYRA)
According to the 24-hour chart, there is a support level at 2.91, which, if violated, would cause prices to drop to 2.33. In the upper region, resistance lies at 4.12. The next price resistance is at 4.75. RSI (Relative Strength Index) is 32.84 on the 14-day chart, showing neutral technical sentiment.
Is Lyra Therapeutics Inc subject to short interest?
Stocks of Lyra Therapeutics Inc saw a sharp rise in short interest on 2025-11-14 jumping by 8565.0 shares to 46498.0. Data from Yahoo Finance shows that the short interest on 2025-10-15 was 37933.0 shares. A jump of 18.42% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 1.45 of the overall float, the days-to-cover ratio (short ratio) jumped to 1.45.
Which companies own the most shares of Lyra Therapeutics Inc (LYRA)?
In terms of Lyra Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 0.5 in the next 12 months, down nearly -82.64% from the previous closing price of $2.88. Analysts anticipate Lyra Therapeutics Inc stock to reach 0.5 by 2025, with the lowest price target being 0.5. In spite of this, 3 analysts ranked Lyra Therapeutics Inc stock as Buy at the end of 2025. On October 06, 2023, BTIG Research assigned a price target of “a Buy” to the stock and resumed coverage with a $15.
